INDIAGLYCO India Glycols Q3 FY26 results (Oct–Dec 2025) and concall
India Glycols reported record revenue and EBITDA for Q3 and 9M FY26, driven by strong performance in Potable Spirits and strategic improvements in Chemicals. The company significantly reduced debt and is focusing on bio-based and premiumization strategies. Challenges persist in Ennature Biopharma and the JV, alongside a volatile global environment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.0%, net profit up 47.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 961 | 975 | 863 | 1,040 | 1,091 +14% | 1,102 +13% |
| EBITDA | 116 | 124 | 144 | 148 | 158 +36% | 176 +42% |
| Net profit | 39 | 44 | 50 | 53 | 54 +38% | 65 +48% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
